BackVertex Pharmaceuticals Overview
Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals Target Price

See Vertex Pharmaceuticals's analyst price targets ($600) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$538.6

Average Target Price

$596.5310.8% upside

15 analysts in the last 4 months

High: $665 | Low: $442

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-11-03Cantor FitzgeraldCarter Gould$61914.9% upsideOpen
2026-11-03Wells FargoMohit Bansal$65020.7% upsideOpen
2026-10-08RBC Capital$5766.9% upsideOpen
2026-09-28UBS$61514.2% upsideOpen
2026-09-23JefferiesAkash Tewari$64018.8% upsideOpen
2026-09-22H.C. WainwrightAndrew Fein$64119% upsideOpen
2026-09-01Morgan StanleyTerence Flynn$66523.5% upsideOpen
2026-09-01Goldman Sachs$65321.2% upsideOpen
2026-08-11BernsteinJeffrey Walch$60812.9% upsideOpen
2026-08-10Wolfe ResearchAndy Chen$5624.3% upsideOpen
2026-08-05Truist Financial$5654.9% upsideOpen
2026-08-05Barclays$61714.6% upsideOpen
2026-08-04Canaccord Genuity$44217.9% downsideOpen
2026-08-04Cantor Fitzgerald$59510.5% upsideOpen
2026-08-04Stifel Nicolaus$5007.2% downsideOpen
2026-07-13Truist Financial$5604% upsideOpen
2026-07-13UBS$5858.6% upsideOpen
2026-07-07RBC Capital$5705.8% upsideOpen
2026-07-07Robert W. Baird$35035% downsideOpen
2026-05-27Truist FinancialDanielle Brill$5420.6% upsideOpen
2026-05-06Barclays$61514.2% upsideOpen
2026-05-05Bernstein$5726.2% upsideOpen
2026-05-05RBC CapitalBrian Abrahams$5430.8% upsideOpen
2026-05-05Canaccord Genuity$43619% downsideOpen
2026-05-05Morgan Stanley$61614.4% upsideOpen
2026-04-30Canaccord Genuity$43718.9% downsideOpen
2026-04-10Morgan Stanley$61213.6% upsideOpen
2026-03-10Truist FinancialJoon Lee$5252.5% downsideOpen
2026-03-10JefferiesAkash Tewari$5807.7% upsideOpen
2026-03-02BMO CapitalEvan David Seigerman$60011.4% upsideOpen
2026-02-17Canaccord Genuity$44118.1% downsideOpen
2026-02-17H.C. WainwrightAndrew Fein$5919.7% upsideOpen
2026-02-17BarclaysEliana Merle$60712.7% upsideOpen
2026-02-13ScotiabankLouise Chen$5583.6% upsideOpen
2026-02-13Morgan StanleyTerence Flynn$5705.8% upsideOpen
2026-02-13H.C. WainwrightAndrew Fein$5183.8% downsideOpen
2026-02-13Stifel NicolausPaul Matteis$46613.5% downsideOpen
2026-02-13Cantor Fitzgerald$5909.5% upsideOpen
2026-02-13Bernstein$5777.1% upsideOpen
2026-02-13RBC Capital$5410.4% upsideOpen
2026-01-27Barclays$60612.5% upsideOpen
2026-01-26UBS$5451.2% upsideOpen
2026-01-23Evercore ISICory Kasimov$5301.6% downsideOpen
2026-01-22RBC CapitalBrian Abrahams$5461.4% upsideOpen
2026-01-06UBSMichael Yee$5350.7% downsideOpen
2025-12-29Leerink Partners$5252.5% downsideOpen
2025-12-05Morgan Stanley$5644.7% upsideOpen
2025-12-03Morgan StanleyTerence Flynn$5164.2% downsideOpen
2025-11-04Cantor FitzgeraldCarter Gould$48510% downsideOpen
2025-11-04RBC Capital$41522.9% downsideOpen

Vertex Pharmaceuticals (VRTX) FAQ

Vertex Pharmaceuticals's target price stands at $600. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $600 for VRTX implies 10.8% upside versus today's price ($538.6). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Vertex Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places VRTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Vertex Pharmaceuticals's reading of $600 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.